Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion

About this update from Cannara Biotech, Inc.

[{"type":"text","content":"Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion\n\n\n\n MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) --\n \n Cannara Biotech Inc.\n \n (“\n \n Cannara\n \n ”, “the\n \n Company\n \n ”, “\n \n us\n \n ” or “\n \n we\n \n ”) (\n \n TSXV: LOVE\n \n ) (\n \n OTCQB: LOVFF\n \n ) (\n \n FRA: 8CB0\n \n ), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce that the common shares of the Company ( “\n \n Common Shares\n \n ”) are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company (“\n \n DTC\n \n ”).\n \n\n DTC eligibility will expand access and reduce costs for U.S. investors purchasing Cannara shares enhancing Cannara’s trading liquidity. As a subsidiary of the Depository Trust & Clearing Corporation, DTC facilitates the electronic clearing and settlement of publicly traded securities in the United States. With this eligibility, the Company’s shares can now be traded through a wider network of U.S. brokerage firms, enabling faster transactions and broader market access.\n \n\n “Achieving DTC eligibility marks an important milestone in our capital markets strategy,” commented Zohar Krivorot, Founder and Chief Executive Officer of Cannara Biotech. “This step makes it easier for American investors to trade our shares, broadens our potential shareholder base, and further enhances Cannara’s visibility in the United States as the industry positions itself for potential federal regulatory reform.”\n \n\n\n Completion of Olymbec Share Issuance\n \n\n\n Further to its news release dated October 2, 2025, the Company is also pleased to announce the completion of the issuance of 3,462,763 Common Shares to Olymbec Investments Inc. (“\n \n Olymbec\n \n ”), at an issue price of $1.80 per share, in full payment of approximately $6.2 million of indebtedness, consisting of $4.7 million in principal and approximately $1.5 million in accrued interest, under its convertible debenture issued to Olymbec, the proceeds ...

More updates from Cannara Biotech, Inc.